Arbutus to present ab-729 and ab-836 data at easl congress 2023

Warminster, pa., june 07, 2023 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that two abstracts have been accepted for poster presentations at the european association for the study of the liver (easl) congress 2023 taking place june 21 - 24, 2023 in vienna, austria.
ABUS Ratings Summary
ABUS Quant Ranking